On blue­bird's heels, CRISPR Ther­a­peu­tics and Ver­tex take the air with in­ter­im CRISPR blood cell ther­a­py da­ta

Pa­tients with se­vere forms of sick­le cell dis­ease or be­ta-tha­lassemia lack enough func­tion­ing red blood cells to shut­tle am­ple oxy­gen through their sys­tems. As a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER